Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M.

N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.

PMID:
31365801
2.

Altered nuclear export signal recognition as a driver of oncogenesis.

Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O.

Cancer Discov. 2019 Jul 8. pii: CD-19-0298. doi: 10.1158/2159-8290.CD-19-0298. [Epub ahead of print]

PMID:
31285298
3.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

4.

Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature.

Rhodes JM, Schuster SJ, Furth EE, Kennard K, Nasta SD, Svoboda J, Porter DL, Mato AR.

Cancer Biol Ther. 2019;20(8):1136-1140. doi: 10.1080/15384047.2019.1598763. Epub 2019 May 15.

PMID:
31091174
5.

PET/Computed Tomography in Chronic Lymphocytic Leukemia and Richter Transformation.

Rhodes JM, Mato AR.

PET Clin. 2019 Jul;14(3):405-410. doi: 10.1016/j.cpet.2019.03.007. Epub 2019 Apr 12. Review.

PMID:
31084779
6.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
7.

Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Mar 28. pii: haematol.2018.207068. doi: 10.3324/haematol.2018.207068. [Epub ahead of print]

8.

Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen.

Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N.

Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102. doi: 10.1016/j.clml.2018.11.010. Epub 2018 Nov 12.

PMID:
30581160
9.

Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?

Sarraf Yazdy M, Mato AR, Cheson BD.

Blood. 2019 Jan 10;133(2):121-129. doi: 10.1182/blood-2018-08-869503. Epub 2018 Nov 14.

PMID:
30429158
10.

Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.

Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR.

Leuk Lymphoma. 2019 Apr;60(4):955-963. doi: 10.1080/10428194.2018.1509320. Epub 2018 Oct 2.

PMID:
30277099
11.

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.

Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:580-591. doi: 10.1200/EDBK_200691. Review.

PMID:
30231393
12.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

PMID:
30132965
13.

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.

Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):673-678. doi: 10.1016/j.clml.2018.06.012. Epub 2018 Jun 15.

PMID:
30033208
14.

Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia.

Bange E, Timlin C, Kabel C, Svoboda J, Roeker L, Mato AR.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e421-e426. doi: 10.1016/j.clml.2018.06.021. Epub 2018 Jun 27. Review.

PMID:
30007569
15.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.

Blood. 2018 Sep 6;132(10):1022-1026. doi: 10.1182/blood-2018-03-837609. Epub 2018 Jun 20.

16.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

17.

Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Tang CH, Chang S, Hashimoto A, Chen YJ, Kang CW, Mato AR, Del Valle JR, Gabrilovich DI, Hu CC.

Cancer Immunol Res. 2018 Jun;6(6):696-710. doi: 10.1158/2326-6066.CIR-17-0582. Epub 2018 Apr 12.

18.

Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.

Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

Cancer Biol Ther. 2018 Jul 3;19(7):636-643. doi: 10.1080/15384047.2018.1449616. Epub 2018 Apr 30.

19.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

20.

Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.

Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J.

Cancer Biol Ther. 2018 Jan 2;19(1):1-2. doi: 10.1080/15384047.2017.1394554. Epub 2017 Dec 27.

21.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

22.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

23.

Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.

Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster SJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):852-856. doi: 10.1016/j.clml.2017.07.007. Epub 2017 Jul 21. Review.

PMID:
28826693
24.

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

Winter AM, Landsburg DJ, Mato AR, Isaac K, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Smith MR, Caimi P, Jagadeesh D, Hill BT.

Blood. 2017 Aug 9. pii: blood-2017-05-786988. doi: 10.1182/blood-2017-05-786988. [Epub ahead of print] No abstract available.

PMID:
28794071
25.

Biosimilars in Oncology in the United States: A Review.

Nabhan C, Parsad S, Mato AR, Feinberg BA.

JAMA Oncol. 2018 Feb 1;4(2):241-247. doi: 10.1001/jamaoncol.2017.2004. Review. Erratum in: JAMA Oncol. 2017 Oct 1;3(10):1431.

PMID:
28727871
26.

Emerging Strategies in Treating Double Hit Lymphomas.

Nabhan C, Mato AR.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):563-568. doi: 10.1016/j.clml.2017.06.017. Epub 2017 Jun 21. Review.

PMID:
28711572
27.

Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.

Nabhan C, Mato AR.

J Clin Oncol. 2017 Jun 1;35(16):1863-1864. doi: 10.1200/JCO.2016.71.9690. Epub 2017 Mar 13. No abstract available.

PMID:
28549225
28.

Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.

Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J.

Am J Hematol. 2017 Sep;92(9):879-884. doi: 10.1002/ajh.24792. Epub 2017 Jun 9.

29.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

30.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

PMID:
28453705
31.

BCL-2 as a therapeutic target in chronic lymphocytic leukemia.

Daniel C, Mato AR.

Clin Adv Hematol Oncol. 2017 Mar;15(3):210-218. Review.

PMID:
28398276
32.

Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C, Schuster SJ.

Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21. No abstract available.

PMID:
28220935
33.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

34.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB.

Blood. 2016 Dec 22;128(25):2899-2908. doi: 10.1182/blood-2016-06-715284. Epub 2016 Nov 1.

35.

Clinical pathways in chronic lymphocytic leukemia: Challenges and solutions.

Nabhan C, Mato AR, Feinberg BA.

Am J Hematol. 2017 Jan;92(1):5-6. doi: 10.1002/ajh.24589. Epub 2016 Nov 18. Review. No abstract available.

36.

Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia.

Wang J, Morrissette J, Lieberman DB, Timlin C, Schuster SJ, Mato AR.

Br J Haematol. 2018 Jan;180(2):299-301. doi: 10.1111/bjh.14315. Epub 2016 Oct 7. No abstract available.

PMID:
27714764
37.

Richter's Transformation in the Era of Kinase Inhibitor Therapy: A Review.

Ayers EC, Mato AR.

Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):1-6. doi: 10.1016/j.clml.2016.08.021. Epub 2016 Sep 8. Review.

PMID:
27707629
38.

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S.

Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.

PMID:
27637985
39.

Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.

Ayers EC, Fardin S, Gholami S, Alavi A, Mato AR.

PET Clin. 2016 Jul;11(3):209-18. doi: 10.1016/j.cpet.2016.02.001. Epub 2016 Mar 26. Review.

PMID:
27321026
40.

Ibrutinib for Chronic Lymphocytic Leukemia.

Sharman JP, Mato AR, Keating MJ.

N Engl J Med. 2016 Apr 21;374(16):1592-3. doi: 10.1056/NEJMc1600328. No abstract available.

PMID:
27096595
41.

Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.

Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, Loren AW, Frey NV, Stadtmauer EA, Porter DL, Schuster SJ, Nasta SD.

Am J Hematol. 2016 Jul;91(7):672-6. doi: 10.1002/ajh.24372. Epub 2016 Apr 24.

42.

Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.

Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ.

Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873. Epub 2015 Dec 23. No abstract available.

43.

Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.

Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A.

Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30.

44.

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, Walsh KM, Schuster SJ.

Clin Cancer Res. 2015 Apr 15;21(8):1835-42. doi: 10.1158/1078-0432.CCR-14-2221. Epub 2015 Jan 28.

45.

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A.

Invest New Drugs. 2014 Dec;32(6):1213-25. doi: 10.1007/s10637-014-0125-2. Epub 2014 Jun 15.

46.

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.

Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A.

Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25.

47.

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.

Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.

Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.

48.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.

Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.

49.

Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.

Mato AR, Feldman T, Goy A.

Oncologist. 2012;17(5):694-707. doi: 10.1634/theoncologist.2011-0341. Epub 2012 May 7. Review.

50.

Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma.

Mato AR, Goy A.

PET Clin. 2012 Jan;7(1):57-65. doi: 10.1016/j.cpet.2011.12.003. Epub 2012 Jan 14.

PMID:
27157018

Supplemental Content

Support Center